Iovance Biotherapeutics, Inc. IOVA Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $71.43M+44.8% | $86.77M+17.7% | $67.46M+15.2% | $59.95M+92.7% | $49.32M+6,798% | ||
| $42.5M-0.5% | $43.11M+14.1% | $38.48M+22.1% | $56.66M+80.6% | $42.72M+488% | ||
| $28.93M+338% | $43.66M+21.6% | $28.98M+7.2% | $3.29M+1,355% | $6.61M+201% | ||
| 40.5%+27.1pp | 50.3%+1.6pp | 43%-3.2pp | 5.5%+6.3pp | 13.4%+929pp | ||
| $62.49M-17.7% | $71.2M+0.3% | $75.17M+12.1% | $79.36M+27.8% | $75.97M-4.8% | ||
| $38.95M-11.1% | $36.4M-14.0% | $34.56M-12.2% | $37.7M-4.7% | $43.8M+39.5% | ||
| $11.27M-50.8% | —— | $11.9M-61.6% | —— | $22.92M— | ||
| $8.54M+5.9% | $9.52M+4.0% | $9.01M-7.4% | $9.35M+212% | $8.07M+171% | ||
| $152.47M-10.6% | $160.23M0.0% | $162.36M+10.0% | $173.73M+30.6% | $170.55M+44.0% | ||
| -$81.04M+33.1% | -$73.46M+15.1% | -$94.9M-6.6% | -$113.77M-11.6% | -$121.22M-3.0% | ||
| -113.5%+132pp | -84.7%+32.8pp | -140.7%+11.4pp | -189.8%+138pp | -245.8%+16,219pp | ||
| $1.33M-58.6% | $1.74M-81.8% | $1.24M-69.0% | $4.1M+22.3% | $3.22M-3.5% | ||
| -$79.71M+32.4% | -$71.72M+6.9% | -$93.66M-10.1% | -$109.67M-11.3% | -$118M-3.2% | ||
| -$665K+63.8% | $0— | -$2.41M-58.2% | $1.99M+236% | -$1.84M-30.5% | ||
| -$79.05M+32.0% | -$71.9M+8.5% | -$91.25M-9.2% | -$111.66M-15.0% | -$116.16M-2.8% | ||
| -110.7%+125pp | -82.9%+23.7pp | -135.3%+7.4pp | -186.2%+126pp | -235.5%+15,565pp | ||
| -$0.19+47.2% | —— | —— | -$0.33+2.9% | -$0.36+14.3% | ||
| -$0.19+47.2% | -$0.15+40.0% | -$0.25+10.7% | -$0.33+2.9% | -$0.36+14.3% | ||
| 418.5M+29.6% | 357.3M+23.3% | —— | 334.5M+17.4% | 322.9M+21.3% | ||
| 418.5M+29.6% | 357.3M+23.3% | 364M+20.0% | 334.5M+17.4% | 322.9M+21.3% | ||
| $1.02M-57.9% | $1.31M-59.0% | $1.41M-54.1% | $2.15M— | $2.42M— | ||
| $5.12M-48.4% | $5.67M-57.8% | $5.01M-63.7% | $6.36M— | $9.92M— | ||
| $5.13M-51.5% | $4.84M-66.3% | $5.48M-61.2% | $6.44M— | $10.58M— | ||
| $71.43M+44.8% | $86.77M+17.7% | $67.46M+15.2% | $59.95M+92.7% | $49.32M+6,798% | ||
| $11.27M-50.8% | $11.82M-61.9% | $11.9M-61.6% | $14.94M-51.0% | $22.92M+33.4% | ||
| —— | $15.39M-43.8% | $15.39M-43.8% | $15.39M-43.8% | $15.39M-43.8% | ||
| -$81.04M+33.1% | -$73.46M+15.1% | -$94.9M-6.6% | -$113.77M-11.6% | -$121.22M-3.0% | ||
| -$78.22M+34.1% | -$69.74M+16.3% | -$91.92M-6.8% | -$110.37M-11.6% | -$118.65M-3.4% | ||
| -$78.22M+34.1% | -$69.74M+16.3% | -$91.92M-6.8% | -$110.37M-11.6% | -$118.65M-3.4% | ||
| -109.5%+131pp | -80.4%+32.7pp | -136.3%+10.7pp | -184.1%+134pp | -240.6%+15,808pp | ||
| -$81.04M+33.1% | -$73.46M+15.1% | -$94.9M-6.6% | -$113.77M-11.6% | -$121.22M-3.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Iovance Biotherapeutics, Inc.'s profit margins?
- Gross margin is 36.7% and operating margin is -127.2%, with a -123.9% net margin.
- Where does Iovance Biotherapeutics, Inc.'s income statement data come from?
- Every line is extracted from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.